Home Nav
Nextech Invest Logo

Kai Wucherpfennig

Alfred Scheidegger

Kai Wucherpfennig MD PhD is Professor and Chair of the Department of Cancer Immunology and Virology at the Dana-Farber Cancer Institute and Professor of Neurology at Harvard Medical School. His research focuses on the discovery of genes that control the activity of cytotoxic T cells in the tumor microenvironment drawing insights for the development of next-generation cancer immunotherapies. He has received a number of honors and awards, including his election as a Fellow in the American Society for the Advancement of Science, his election as a member of the Henry Kunkel Society at Rockefeller University, and his election as a member of the American Society for Clinical Investigation. Dr Wucherpfennig serves as an advisor to a number of immuno-oncology companies and since 2015 is an exclusive scientific board member of Nextech Invest.

 

17th Annual Biotech in Europe Forum

26.09. – 27.09.2017

Basel

  • 10.09.2017

    Blueprint Medicines announces new data from ongoing...

  • 07.09.2017

    TRACON Pharmaceuticals announces completion of enrollment...

  • 07.09.2017

    Kura Oncology announces positive Phase II study for...

Close

Newsletter Registration

Please fill in the subscription form completely. If you wish to modify your personal data or to change/cancel your newsletter subscription, this is possible at any time.

A link to your subscription profile can be found in every newsletter email.

Preview

* Compulsory fields

Close

Newsletter Registration

Your eMail have been successfully registered.

Close